This site is intended for health professionals only

Approval for APP infection drug

teaser

APP Pharmaceuticals has received marketing approval for its generic anti-infective treatment, Aztreonam.

The Food and Drug Administration passed the product for injection in 1g 20ml and 2g 30ml strengths.

The company plans to launch Aztreonam, which is said to be therapeutically equivalent to the Bristol-Myers Squibb’s Azactam, immediately.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

John Ducker, president and chief executive officer of APP Pharmaceuticals, said: “This approval reinforces APP’s commitment to provide our customers, and the patients they treat, with a consistently expanding portfolio of products.”

Aztreonam is used to treat urinary tract, gynecologic and skin infections.

APP Pharmaceuticals is a subsidiary of Fresenius Kabi Pharmaceuticals.

Copyright Press Association 2010
APP Pharmaceuticals






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x